Citi analyst Joanne Wuensch lowered the firm’s price target on Establishment Labs (ESTA) to $65 from $74 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs selloff ‘unwarranted and overdone,’ says Mizuho
- Establishment Labs price target lowered to $74 from $81 at Citi
- Establishment Labs Earnings Call Signals Profitable Growth
- Establishment Labs price target raised to $90 from $85 at Canaccord
- Establishment Labs price target raised to $90 from $85 at Stephens